Cantor Fitzgerald Initiates Coverage on Karyopharm Therapeutics (NASDAQ:KPTI)

Equities research analysts at Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note issued to investors on Thursday. The firm set an “overweight” rating on the stock.

Several other research analysts have also commented on KPTI. Wall Street Zen raised Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 8th. The Goldman Sachs Group set a $12.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Robert W. Baird decreased their price objective on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, October 9th. HC Wainwright upgraded Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 price objective on the stock in a report on Monday, October 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.83.

Karyopharm Therapeutics Stock Down 3.8%

Shares of NASDAQ KPTI opened at $6.30 on Thursday. The stock has a market capitalization of $115.35 million, a PE ratio of -0.43 and a beta of 0.21. The firm has a fifty day moving average of $6.77 and a 200-day moving average of $6.10. Karyopharm Therapeutics has a 52-week low of $3.51 and a 52-week high of $10.38.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($3.82) EPS for the quarter, missing the consensus estimate of ($3.30) by ($0.52). The business had revenue of $44.04 million during the quarter, compared to the consensus estimate of $39.56 million. Equities research analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its position in shares of Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after purchasing an additional 35,626 shares during the period. Silverback Asset Management LLC lifted its stake in Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after acquiring an additional 20,000 shares in the last quarter. Bridgeway Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the second quarter worth approximately $163,000. ADAR1 Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics during the 3rd quarter worth about $164,000. Finally, XTX Topco Ltd bought a new stake in Karyopharm Therapeutics in the second quarter worth $56,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.